for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Limited

TEVA.TA

Latest Trade

2,870.00ILa

Change

62.00(+2.21%)

Volume

1,577,117

Today's Range

2,770.00

 - 

2,880.00

52 Week Range

2,175.00

 - 

8,936.00

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,808.00
Open
2,770.00
Volume
1,577,117
3M AVG Volume
46.52
Today's High
2,880.00
Today's Low
2,770.00
52 Week High
8,936.00
52 Week Low
2,175.00
Shares Out (MIL)
1,091.00
Market Cap (MIL)
31,511.22
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Intercure Says Unit Canndoc Entered Strategic Distribution Agreement With Teva Pharmaceuticals Unit

Teva Canada Announces Approval Of Herzuma

Allergan Announces Settlement With Two Ohio Plaintiffs In Federal Opioid Litigation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry

Biotechnology & Drugs

Contact Info

5 Basel St.,

P.O. Box 3190

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Michael James McClellan

Chief Financial Officer, Executive Vice President

Iris Beck-Codner

Executive Vice President - Global Brand & Communications

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.50
Price To Book (MRQ)
0.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
203.40
LT Debt To Equity (MRQ)
183.78
Return on Investment (TTM)
-8.74
Return on Equity (TTM)
-6.58

Latest News

Teva launches generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan's EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.

Teva to launch generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

Teva settles multibillion-dollar drug kickback case ahead of trial

Teva Pharmaceutical Industries Ltd has agreed on the eve of trial to settle a multibillion-dollar whistleblower lawsuit alleging it paid doctors kickbacks to prescribe its Parkinson's disease drug Azilect and multiple sclerosis treatment Copaxone.

Judge certifies Niaspan 'pay-for-delay' class action against AbbVie, Teva

A federal judge on Wednesday certified a class of drug purchasers suing AbbVie Inc and Teva Pharmaceutical Industries Ltd over an alleged anticompetitive agreement that delayed the release of a generic version of the cholesterol drug Niaspan.

U.S. lawmakers push Mylan, Teva over drug pricing probe

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Israel's Teva Pharm profit falls less than expected, CFO to leave

Teva Pharmaceutical Industries <TEVA.TA> reported a smaller-than-expected drop in second-quarter profit on Wednesday and said its chief financial officer was leaving the company.

Israel's Teva Pharm Q2 profit falls less than expected

Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and reaffirmed its full year outlook.

Teva settles California's Provigil pay-for-delay claims for $69 million

California's attorney general on Monday said Teva Pharmaceutical Industries Ltd had reached a $69 million settlement resolving claims it engaged in an anticompetitive scheme that delayed the release of cheaper generic versions of the wakefulness drug Provigil.

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.

Oklahoma judge approves Teva's $85 million opioid settlement

An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

Oklahoma judge approves Teva's $85 million opioid settlement

An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

Oklahoma judge mulls governor's concerns over Teva opioid settlement

An Oklahoma judge on Monday asked the state's attorney general to respond to arguments by the state's governor and legislative leaders that Teva Pharmaceutical Industries Ltd's $85 million opioid litigation settlement violates a new law they say requires the funds to be...

Teva Pharm to pay Oklahoma $85 million to settle opioid claims

Teva Pharmaceutical Industries Ltd said on Sunday it had agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped fuel the U.S. opioid epidemic.

Oklahoma reaches $85 mln settlement with Teva Pharmaceuticals ahead of trial

Oklahoma has reached a $85 million settlement agreement with Israeli-based Teva Pharmaceutical Industries Ltd ahead of the start of a trial in a multibillion-dollar lawsuit over the opioid epidemic, the state's attorney general said on Sunday.

J&J, Teva lose last-minute bid to escape Oklahoma opioid lawsuit

An Oklahoma judge on Monday cleared the way for Johnson & Johnson and Teva Pharmaceutical Industries Ltd to face trial at the end of May in a lawsuit by the state's attorney general accusing the drugmakers of helping fuel the opioid epidemic.

Teva Pharm CFO says company did not conspire to fix prices

Teva Pharmaceutical Industries' chief financial officer on Sunday reiterated that the company has done nothing wrong in the wake of a price-fixing lawsuit filed by 44 U.S. states.

U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices - sometimes by more than 1,000% - and stifle competition for generic drugs, state prosecutors said on Saturday.

U.S. states sue Teva, 19 other drug companies in price-fixing complaint

Forty-four U.S. states have filed a lawsuit accusing 20 drug companies including Teva Pharmaceuticals USA Inc of a sweeping scheme to inflate drug prices and stifle competition for more than 100 generic drugs, state prosecutors said on Saturday.

Teva's new migraine drug helps to contain profit fall

Israel-based Teva Pharmaceutical Industries Ltd on Thursday forecast a sharp rise in revenue next year from its new migraine drug Ajovy and reported a slightly smaller-than-expected drop in first-quarter profit.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up